Abstract
Pigmented paraganglioid carcinoid tumors (PPCT) of the lung are a rare, underrecognized, and poorly characterized morphologic variant of pulmonary neuroendocrine tumors (NETs). While these tumors are usually diagnosed as typical carcinoid (TC) tumors, PPCT may represent a diagnostic challenge due to the histologic resemblance with extra-adrenal paraganglioma (PG). In this study, we aimed to comprehensively characterize the histomorphologic, immunophenotypic, and transcriptomic profiles of PPCT in comparison to TC and PG using spatially resolved transcriptomic analysis. Using a tissue microarray (TMA) composed of 38 tumors, including 20 TC, 16 PG, and 2 PPCT, we performed immunohistochemical (IHC) and digital spatial transcriptomic (GeoMx® DSP) profiling. The TMA included two punches and two regions of interest (ROIs) per case. Cellular transcriptomes were selected based on epithelial (PanCK+), sustentacular (S100+), and immune (CD45+) compartments. By IHC, PPCT retained neuroendocrine markers (synaptophysin, INSM1, chromogranin A) but showed decreased or absent pancytokeratin cocktail expression and increased number of sustentacular cells highlighted by strong expression of S100 and SOX-10, similar to PG. Expression of AE1/AE3 and CK8/18 confirmed their epithelial origin and helped distinguish them from PG. The transcriptome of PPCT clustered with that of TC but displayed distinct expression patterns in a small subset of genes. Although the sustentacular and immune compartments showed limited divergence, the epithelial compartment showed differentially expressed genes in PPCT including FABP5, MLPH, GPNMB, and SOX1, which indicate upregulation of melanocytic and neural crest markers. Gene set enrichment analysis (GSEA) revealed significant upregulation of pathways related to inflammation (e.g., TLR4-TRAF6-TAK1), PTEN trafficking, and inositol phosphate metabolism. PPCT show increased melanocytic pathway expression, which may explain the morphologic resemblance to PG.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R.R.-C. received Intradepartmental Pilot funding from the Department of Pathology and Laboratory Medicine. This study was performed in part at the Onco-Genomics Shared Resource (OGSR): SCR_022502 of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, which is supported by the National Cancer Institute Cancer Center Support Grant (CCSG) P30-CA240139.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University of Miami Miller School of Medicine gave ethical approval for this work (IRB# 20180047).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The original contributions presented in this work are included in the article. Further inquiries can be directed to the senior author.
